New Enhancing MRI Lesions Associate with IL-17, Neutrophil Degranulation and Integrin Microparticles: Multi-Omics Combined with Frequent MRI in Multiple Sclerosis

Keyphrases

• 3T MRI 10%
• Active Inflammation 10%
• Activity Comparison 30%
• Activity Groups 10%
• Acute Phase Proteins 10%
• Alternative Complement Pathway 10%
• Array Data 10%
• Array-based 10%
• Blood Coagulation 10%
• Brain Inflammation 10%
• CCL17 10%
• CCL3 10%
• CD62E 10%
• Circulating Immune Cells 10%
• Coagulation Cascade 10%
• Coagulation System 10%
• Complement Activation 10%
• Complement Components 10%
• Composite Biomarkers 10%
• Contrast-enhancing Lesions 10%
• Disease-modifying Therapy 10%
• Early Markers 10%
• Endothelial Dysfunction 10%
• Endothelial Junctions 10%
• Endothelial Stress 20%
• Exosomes 10%
• Extracellular Matrix Organization 10%
• Extracellular Vesicles 100%
• Fluid-attenuated Inversion Recovery (FLAIR) 30%
• Functional Enrichment 10%
• Gadolinium 10%
• Gadolinium-enhancing Lesions 30%
• Hierarchical Clustering 10%
• High Protein 10%
• High-resolution 10%
• IL-12p40 10%
• IL-12p70 10%
• IL-6 Level 10%
• Inflammation 10%
• Inflammatory Biomarkers 10%
• Initial Event 10%
• Innate Immune Response 10%
• Integrin 100%
• Intercellular Adhesion molecule-1 (ICAM-1) 20%
• Interleukin-17 (IL-17) 100%
• Interleukin-1β 30%
• Interleukin-7 (IL-7) 10%
• Intravenous Gadolinium 20%
• Late Gadolinium Enhancement 10%
• Lesion Enhancement 10%
• Lesion Evolution 10%
• Linear Mixed Model 10%
• Marker Array 10%
• Microparticles 100%
• MIP-1b 10%
• Molecular Events 10%
• MRI Activity 70%
• MRI Lesions 100%
• MRI Outcomes 40%
• MRI Scan 10%
• Multi-omics 100%
• Multiple Sclerosis 100%
• Multiplex Immunoassay 20%
• Neuroinflammation Markers 10%
• Neutrophil Degranulation 100%
• New Lesion 50%
• Patient Time 10%
• Plasma Profile 10%
• Plasma Samples 10%
• Principal Coordinate Analysis (PCoA) 10%
• Protein Array 10%
• Protein Biomarkers 10%
• Protein Changes 10%
• Protein Markers 10%
• Proteome 10%
• Proteomic Analysis 10%
• Proteomics 10%
• Quantitative Proteomics 10%
• Random Forest 10%
• Relapsing-remitting multiple Sclerosis 30%
• Soluble Markers 10%
• Surface Proteins 10%
• Temporal Change 10%
• Th17 Pathway 20%
• Up-regulated Proteins 10%

Immunology and Microbiology

• Acute Phase Protein 5%
• Alternative Complement Pathway 5%
• Blood Clotting 11%
• Blood Plasma 22%
• CCL17 5%
• CCL3 5%
• Complement 5%
• Complement Activation 5%
• Cytokine 11%
• Degranulation 100%
• Exosome 5%
• Extracellular Matrix 5%
• Immunoassay 11%
• Immunocompetent Cell 5%
• Innate Immune System 5%
• Integrin 100%
• Intercellular Adhesion Molecule 1 11%
• Interleukin 1 16%
• Interleukin 17 100%
• Interleukin 6 5%
• Interleukin 7 5%
• Magnetic Resonance Imaging 100%
• Minimum Inhibitory Concentration 5%
• Multi-Omics 100%
• Multiple Sclerosis 100%
• Neutrophil 100%
• Proteomics 16%
• Random Forest 5%
• Thymus and Activation Regulated Chemokine 5%
• Tumor Necrosis Factor 5%

Biochemistry, Genetics and Molecular Biology

• Acute Phase Protein 5%
• Alternative Complement Pathway 5%
• Blood Plasma 22%
• CCL17 5%
• CCL3 5%
• Coagulation System 11%
• Complement Activation 5%
• Cytokine 11%
• Degranulation 100%
• Gadolinium 38%
• ICAM-1 11%
• Immunoassay 11%
• Immunocompetent Cell 5%
• Innate Immunity 5%
• Integrin 100%
• Interleukin 17 100%
• Interleukin 6 5%
• Interleukin 7 5%
• Interleukin-1 16%
• Magnetic Resonance Imaging 100%
• Microvesicles 55%
• Minimum Inhibitory Concentration 5%
• Neuroinflammation 5%
• Principal Component Analysis 5%
• Protein Microarray 5%
• Proteome 5%
• Proteomics 11%
• Quantitative Proteomics 5%
• Random Forest 5%
• Tamsulosin 100%
• Tumor Necrosis Factor 5%